The time is now: implementing a multidisciplinary approach to metabolic dysfunction-associated steatotic liver disease ​(MASLD*/NAFLD) management

Novo Nordisk A/S and Echosens |
Tuesday

Chairs: Lise Lotte Gluud (DNK), Cyrielle Caussy (FRA)

16:45 – 16:47IntroductionLise Lotte Gluud (DNK)
Cyrielle Caussy (FRA)
16:47 – 16:52Screening for MASLD*/NAFLD: the who, when and why nowLise Lotte Gluud (DNK)
Cyrielle Caussy (FRA)
16:52 – 17:07Integrating MASLD*/NAFLD management into multidisciplinary careLise Lotte Gluud (DNK)
Cyrielle Caussy (FRA)
17:07 – 17:14Q & ALise Lotte Gluud (DNK)
Cyrielle Caussy (FRA)
17:14 – 17:15Summary and closure

Lise Lotte Gluud (DNK)
Cyrielle Caussy (FRA)

*formerly known as NAFLD